Agrimonolide shows benefits in cholestasis mouse model
Agrimonolide, a molecule found in a traditional Chinese herb, eased liver damage, scarring, and inflammation in a mouse model of cholestasis, a study showed.
Lindsey Shapiro, PhD, Science Writer—
Articles by Lindsey Shapiro
Liver Foundation honors family who turned diagnosis into giving
A family whose experience with biliary atresia led to an effort to help others navigate the challenges of pediatric liver disease is among those being…
PFIC Awareness Day means… spotlighting the rare liver disease
Supporters are gearing up for the 7th Annual PFIC Awareness Day on Oct. 5, with advocates behind the yearly event focused on improving public awareness,…
Phase 2 trial of volixibat for PSC-related itching now fully enrolled
Enrollment is complete in the Phase 2b VISTAS clinical trial, which is testing the experimental oral treatment volixibat in people with itching due to…
PBC treatment Ocaliva leaves U.S. market amid safety concerns
Intercept Pharmaceuticals has voluntarily withdrawn Ocaliva (obeticholic acid), an oral therapy used to treat certain adults with primary biliary cholangitis (PBC), from…
FDA weighs noninvasive biopsy alternative in MASH clinical trials
The U.S. Food and Drug Administration (FDA) will evaluate the use of Fibroscan, a noninvasive test, to replace liver biopsies in clinical trials for metabolic…
Virtual 5K expands annual run into national biliary atresia fundraiser
An annual fundraising run in the Washington area becomes a monthlong, virtual event this year to raise funds and awareness for the rare pediatric liver…
Phase 3 Trial of brelovitug for hepatitis D enrolls 1st patient
The first participant has been enrolled in a Phase 3 clinical trial testing Bluejay Therapeutics’ investigational therapy brelovitug against bulevirtide in adults with chronic…
Treatment of hepatitis B needs global overhaul, per WHO study
Current approaches to hepatitis B care across the globe are failing to adequately connect patients with treatment, and also to retain them for long-term…
Dosing begins in Phase 2 trial of ALG-000184 for hepatitis B
The first participant has been dosed in a Phase 2 clinical trial testing Aligos Therapeutics’ oral treatment candidate ALG-000184 in people chronically infected with…